Can dasatinib be taken long-term?

Dasatinib (Dasatinib) is a targeted drug mainly used to treat certain types of blood tumors, especially chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It is a second-generation tyrosine kinase inhibitor that can effectively inhibit the activity of BCR-ABL fusion protein, thereby preventing the proliferation and survival of tumor cells. Dasatinib inhibits the growth of cancer cells by binding to tyrosine kinases and interfering with their normal functions.

In the treatment of chronic myeloid leukemia, dasatinib is usually used in patients who are resistant or intolerant to first-generation drugs such as imatinib (Imatinib). Clinical studies have shown that dasatinib can significantly improve patients' complete response rate and disease-free survival. Therefore, it is often considered an effective second-line treatment option. At the same time, in the treatment of acute lymphoblastic leukemia, dasatinib is also used as a treatment for certain subtypes, especially in cases of B cell precursors, showing good efficacy.

Regarding the long-term use of dasatinib, although the drug has shown good tolerability and efficacy in many patients, the feasibility of long-term use still needs to be evaluated based on the specific condition and individual response. Typically, doctors decide whether to continue using a drug based on the patient's response to treatment, drug side effects, and other related health conditions. Some patients may require dose adjustments or switching to other treatment regimens after long-term use.

After treatment effects are achieved, doctors may periodically monitor the patient's blood markers to assess the tumor's response and drug tolerance. While using dasatinib, patients need to undergo regular examinations, including blood routine, liver and kidney function, etc., to detect possible side effects in a timely manner.